Sore, stiff joints are more than just a nuisance. When pain flares up, it can sometimes make even simple tasks like driving or writing challenging. But what you might not know is that if your joint ...
Psoriatic arthritis (PsA) is an inflammatory disease marked by its multi-domain involvement, from the peripheral and axial joints, skin and nails, enthesitis, eyes, and digits. 1 This complex ...
Like many chronic conditions, psoriatic arthritis (PsA) isn’t something you manage just once. Your psoriatic arthritis treatment journey might be more of a marathon than a sprint, with a few ...
Psoriatic arthritis (PsA) flares are often unpredictable. However, knowing the signs a flare may be coming, such as exposure to a trigger, worsening skin, and more, can help a person take action to ...
Rachel Tavel is a doctor of physical therapy, certified strength and conditioning specialist and writer. She works as a physical therapist in an outpatient orthopedic physical therapy setting and as a ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower ...
Verywell Health on MSN
What to Expect as Psoriatic Arthritis Progresses in Stages
Medically reviewed by Anita C. Chandrasekaran, MD Key Takeaways Psoriatic arthritis (PsA) progresses through four stages: ...
Please provide your email address to receive an email when new articles are posted on . Patients with psoriatic arthritis who received 30 mg and 60 mg daily doses of brepocitinib had significantly ...
Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA ...
Treating psoriatic arthritis (PsA) isn't like treating strep throat. You don't just take one medicine for a few days and feel better. PsA is a complex, chronic disease that stays with you and affects ...
(RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback